The Debate Valeant, Drug Prices And Innovation
Not even Valeant wants to be associated with Valeant anymore. Its share prices have plummeted, it is saddled with $29.8 billion in debt, and lawsuits against it are in motion. Its public image has tanked so badly that according to … Read More »